Compare Cintas Corporation (CTAS) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Eli Lilly And Co — how do they compare? Cintas Corporation trades at $203.77 (market cap $82.15B), while Eli Lilly And Co trades at $1,204 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 13.1× Cintas Corporation's market cap, and Cintas Corporation pays the higher dividend (1.01%). Which is the better fit depends on your goals.
| CTAS | LLY | |
|---|---|---|
Market Cap | $82.15B | $1.08T |
Sector | Industrials | Health |
52-Week High | $225.10 | $1.24K |
52-Week Low | $163.55 | $639.43 |
Enterprise Value | $84.56B | $1.13T |
Dividend Yield | 1.01% | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTAS trades at $203.06, showing modest daily gains. The stock exhibits a bullish technical trend, supported by recent earnings beats and strong profitability metrics, including a 17.75% net income margin. Recent news highlights dividend declarations and positive analyst upgrades following Q4 2026 results.
The outlook is positive, with revenue growth and margin expansion driving upside potential toward the $225.83 consensus price target. Risks include elevated valuation multiples and macroeconomic sensitivity. Institutional activity shows mixed positioning, but overall sentiment leans bullish.
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
